Rossari Biotech quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	698	586	+19.0%
EBITDA	87.0	71.9	+20.9%
EBITDA margin	12.5%	12.3%	+0.2 pts
Profit before tax	48.8	49.2	−0.8%
Net profit	38.9	36.9	+5.5%
EPS	₹7.02	₹6.66	+5.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	698	697	685	582	586	544	580	513	498	490	473	464	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.6	3.2	19.1	0.5	1.6	1.2	1.8	0.6	0.7	0.9	0.4	3.5
	698	700	704	582	588	545	581	513	499	491	473	467
	476	515	444	418	407	334	370	321	324	284	304	291
	17.8	14.7	24.1	11.0	29.4	29.0	33.9	46.0	42.3	42.6	38.7	25.3
	−16.1	−38.5	27.2	−27.8	−35.7	8.0	−2.0	−17.4	−26.0	14.3	−4.3	6.7
	43.6	44.0	39.2	40.3	37.8	37.5	35.5	35.7	32.6	28.6	25.0	26.0
	8.7	11.0	9.1	7.7	6.1	5.7	5.5	4.9	3.7	3.7	2.5	4.3
	30.1	25.6	23.5	19.6	18.2	17.7	18.2	18.3	15.2	15.4	16.1	15.1
	89.7	81.7	72.7	71.8	75.5	67.0	72.9	62.2	59.1	55.3	45.8	51.1
	649	653	640	540	539	499	534	471	451	444	428	420
	87.0	80.6	77.3	68.9	71.9	67.9	69.5	64.8	65.9	64.9	63.6	63.7
	56.9	55.0	53.7	49.3	53.7	50.1	51.3	46.4	50.8	49.5	47.5	48.6
Profit
	48.8	47.2	63.7	42.1	49.2	45.6	47.6	42.0	47.8	46.8	45.4	47.8
	48.8	47.2	63.7	42.1	49.2	45.6	47.6	42.0	47.8	46.8	45.4	47.8
	12.3	16.1	15.9	13.2	16.1	16.1	14.4	14.4	15.0	15.3	12.7	15.9
	−1.9	−3.5	2.4	−3.5	−3.3	−3.6	−1.2	−3.7	−2.2	−3.2	−1.3	−2.5
	10.4	12.6	18.3	9.7	12.8	12.5	13.3	10.7	12.8	12.1	11.4	13.4
	0.5	0.5	0.5	0.4	0.5	0.5	0.1	0.3	0.3	0.2	0.2	0.0
	38.9	35.1	46.0	32.8	36.9	33.6	34.4	31.7	35.3	34.9	34.1	34.4
	38.4	34.6	45.5	32.4	36.4	33.1	34.3	31.4	35.0	34.7	33.9	34.4
	0.7	0.4	0.6	−0.2	−0.3	−0.1	−1.1	0.1	0.0	0.0	−0.2	0.1
	39.6	35.4	46.6	32.6	36.6	33.5	33.3	31.8	35.3	34.9	33.9	34.5
	38.9	35.1	46.0	32.8	36.9	33.6	34.4	31.7	—	—	34.1	34.4
Per share
	₹7.02	₹6.34	₹8.30	₹5.92	₹6.66	₹6.07	₹6.22	₹5.73	₹6.39	₹6.32	₹6.18	₹6.23
	₹7.02	₹6.33	₹8.29	₹5.91	₹6.65	₹6.06	₹6.21	₹5.72	₹6.38	₹6.30	₹6.17	₹6.21
Other comprehensive income — detail
	0.7	0.4	0.6	−0.2	−0.3	−0.1	−1.1	—	—	—	—	—
	0.0	0.1	1.1	−0.3	−0.3	−0.3	−1.4	0.1	0.0	0.0	−0.3	0.1
	0.0	0.0	0.3	−0.1	−0.1	−0.1	−0.4	—	—	—	—	—
	—	—	—	—	—	—	—	0.0	0.0	0.0	−0.1	0.0
	0.8	0.4	−0.3	0.0	—	0.1	—	—	—	—	—	—
	0.2	0.1	−0.1	0.0	0.0	0.0	0.1	—	—	—	—	—
	39.6	35.4	46.6	32.6	36.6	33.5	33.3	31.8	35.3	34.9	33.9	34.5
Per share — as-filed variants
	₹7.02	₹6.34	₹8.30	₹5.92	₹6.66	₹6.07	₹6.22	₹5.73	₹6.39	₹6.32	₹6.18	₹6.23
	₹7.02	₹6.33	₹8.29	₹5.91	₹6.65	₹6.06	₹6.21	₹5.72	₹6.38	₹6.30	₹6.17	₹6.21
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	220	206	189	181	185	172	178	163	158	149	134	141
	31.6%	29.6%	27.6%	31.1%	31.6%	31.7%	30.7%	31.7%	31.6%	30.4%	28.4%	30.4%
Adjusted (ex-exceptional items) — derived
	48.8	47.2	63.7	42.1	49.2	45.6	47.6	42.0	47.8	46.8	45.4	47.8
	38.9	35.1	46.0	32.8	36.9	33.6	34.4	31.7	35.3	34.9	34.1	34.4
	₹7.02	₹6.34	₹8.30	₹5.92	₹6.66	₹6.07	₹6.22	₹5.73	₹6.39	₹6.32	₹6.18	₹6.23

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ROSSARI₹415.00

Rossari Biotech Limited

· Chemicals

Annual Quarterly₹ CrorePeersNOCIL HSCL NAVINFLUOR DDEVPLSTIK CHEMPLASTS TATACHEM AARTIIND JGCHEMMcap ₹2,298 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	463.8	472.7	489.7	498.4	512.7	579.6	543.7	586.1	581.7	684.9	697.2	697.6
Other Income	3.5	0.4	0.9	0.7	0.6	1.8	1.2	1.6	0.5	19.1	3.2	0.6
Total Income	467.3	473.1	490.6	499.1	513.3	581.4	544.9	587.7	582.2	703.9	700.4	698.2
Expenses
+ Cost of Materials Consumed	291.0	303.9	284.0	324.4	321.5	369.8	334.4	407.2	417.6	444.5	514.7	475.6
+ Purchases of Stock-in-Trade	25.3	38.7	42.6	42.3	46.0	33.9	29.0	29.4	11.0	24.1	14.7	17.8
+ Changes in Inventories	6.7	-4.3	14.3	-26.0	-17.4	-2.0	8.0	-35.7	-27.8	27.2	-38.5	-16.1
+ Employee Benefit Expense	26.0	25.0	28.6	32.6	35.7	35.5	37.5	37.8	40.3	39.2	44.0	43.6
+ Finance Costs	4.3	2.5	3.7	3.7	4.9	5.5	5.7	6.1	7.7	9.1	11.0	8.7
+ Depreciation & Amortisation	15.1	16.1	15.4	15.2	18.3	18.2	17.7	18.2	19.6	23.5	25.6	30.1
+ Other Expenses	51.1	45.8	55.3	59.1	62.2	72.9	67.0	75.5	71.8	72.7	81.7	89.7
Total Expenses	419.5	427.7	443.8	451.3	471.2	533.8	499.3	538.5	540.1	640.2	653.2	649.4
EBITDA	63.7	63.6	64.9	65.9	64.8	69.5	67.9	71.9	68.9	77.3	80.6	87.0
EBIT	48.6	47.5	49.5	50.8	46.4	51.3	50.1	53.7	49.3	53.7	55.0	56.9
Profit
PBT before Exceptional Items	47.8	45.4	46.8	47.8	42.0	47.6	45.6	49.2	42.1	63.7	47.2	48.8
Pretax Income	47.8	45.4	46.8	47.8	42.0	47.6	45.6	49.2	42.1	63.7	47.2	48.8
+ Current Tax	15.9	12.7	15.3	15.0	14.4	14.4	16.1	16.1	13.2	15.9	16.1	12.3
+ Deferred Tax	-2.5	-1.3	-3.2	-2.2	-3.7	-1.2	-3.6	-3.3	-3.5	2.4	-3.5	-1.9
Tax Expense	13.4	11.4	12.1	12.8	10.7	13.3	12.5	12.8	9.7	18.3	12.6	10.4
+ Share of Associates & JVs	0.0	0.2	0.2	0.3	0.3	0.1	0.5	0.5	0.4	0.5	0.5	0.5
Net Income	34.4	34.1	34.9	35.3	31.7	34.4	33.6	36.9	32.8	46.0	35.1	38.9
+ Net Income — Continuing Ops	34.4	33.9	34.7	35.0	31.4	34.3	33.1	36.4	32.4	45.5	34.6	38.4
+ Other Comprehensive Income	0.1	-0.2	0.0	0.0	0.1	-1.1	-0.1	-0.3	-0.2	0.6	0.4	0.7
Total Comprehensive Income	34.5	33.9	34.9	35.3	31.8	33.3	33.5	36.6	32.6	46.6	35.4	39.6
Net Income to Common	34.4	34.1	—	—	31.7	34.4	33.6	36.9	32.8	46.0	35.1	38.9
Per Share
Basic EPS	6.23	6.18	6.32	6.39	5.73	6.22	6.07	6.66	5.92	8.30	6.34	7.02
Diluted EPS	6.21	6.17	6.30	6.38	5.72	6.21	6.06	6.65	5.91	8.29	6.33	7.02
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-1.1	-0.1	-0.3	-0.2	0.6	0.4	0.7
+ Items NOT to be Reclassified to P&L	0.1	-0.3	0.0	0.0	0.1	-1.4	-0.3	-0.3	-0.3	1.1	0.1	0.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-0.4	-0.1	-0.1	-0.1	0.3	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-0.1	0.0	0.0	0.0	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	—	—	—	0.1	—	0.0	-0.3	0.4	0.8
+ Tax on Items to be Reclassified	—	—	—	—	—	0.1	0.0	0.0	0.0	-0.1	0.1	0.2
Comprehensive Income — Owners of Parent	34.5	33.9	34.9	35.3	31.8	33.3	33.5	36.6	32.6	46.6	35.4	39.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	6.23	6.18	6.32	6.39	5.73	6.22	6.07	6.66	5.92	8.30	6.34	7.02
Diluted EPS — Continuing Operations	6.21	6.17	6.30	6.38	5.72	6.21	6.06	6.65	5.91	8.29	6.33	7.02
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	140.8	134.4	148.7	157.7	162.7	177.9	172.4	185.3	180.9	189.1	206.4	220.3
Gross Margin %	30.36	28.44	30.38	31.63	31.73	30.70	31.70	31.61	31.10	27.62	29.60	31.57
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	47.8	45.4	46.8	47.8	42.0	47.6	45.6	49.2	42.1	63.7	47.2	48.8
Net Income Adj (tax-effected)	34.4	34.1	34.9	35.3	31.7	34.4	33.6	36.9	32.8	46.0	35.1	38.9
EPS Adj	6.23	6.18	6.32	6.39	5.73	6.22	6.07	6.66	5.92	8.30	6.34	7.02
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	—	2.00	2.00	2.00
Paid Up Equity Capital	11.0	11.0	11.0	11.1	11.1	11.1	11.1	11.1	11.1	11.1	11.1	11.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Rossari Biotech Q2 FY27 results (July–September 2026)

Rossari Biotech (NSE: ROSSARI) reported its Q2 FY27 results (July–September 2026). Consolidated net profit was ₹38.9 crore, up 5.5% from ₹36.9 crore in Q2 FY26 and up 10.9% from ₹35.1 crore in Q1 FY27. Revenue from operations was ₹698 crore, up 19.0% year on year and up 0.1% from the previous quarter.

Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹38.9 Cr+5.5% vs Q2 FY26+10.9% vs Q1 FY27
Revenue from operations: ₹698 Cr+19.0% vs Q2 FY26+0.1% vs Q1 FY27
Operating margin (EBIT): 8.2%−1.0 pts vs Q2 FY26+0.3 pts vs Q1 FY27EBIT ₹56.9 Cr
EBITDA: ₹87 Cr+20.9% vs Q2 FY26+7.9% vs Q1 FY27margin 12.5%
Earnings per share (basic): ₹7.02+5.4% vs Q2 FY26+10.7% vs Q1 FY27
Net profit margin: 5.6%−0.7 pts vs Q2 FY26+0.5 pts vs Q1 FY27

Questions

What was Rossari Biotech's net profit in Q2 FY27?

Consolidated net profit was ₹38.9 crore, up 5.5% from ₹36.9 crore in Q2 FY26 and up 10.9% from ₹35.1 crore in Q1 FY27.

What is Rossari Biotech's net profit margin?

Rossari Biotech's net profit margin was 5.6% in Q2 FY27 (net profit as a share of revenue from operations), against 6.3% in Q2 FY26 (down 0.7 percentage points). For FY26 as a whole it was 6.2%.

What was Rossari Biotech's net profit in FY26?

Consolidated net profit was ₹149 crore in FY26 (April 2025–March 2026), up 9.4% from ₹136 crore in FY25. It was ₹131 crore in FY24 and ₹107 crore in FY23: up 39.1% over three years, 11.6% a year on average.

What was Rossari Biotech's revenue in Q2 FY27?

Revenue from operations was ₹698 crore, up 19.0% year on year and up 0.1% from the previous quarter.

What was Rossari Biotech's EPS in Q2 FY27?

Basic earnings per share were ₹7.02, against ₹6.66 in Q2 FY26.

What was Rossari Biotech's revenue in FY26?

Revenue from operations was ₹2,396 crore in FY26 (April 2025–March 2026), up 15.2% from ₹2,080 crore in FY25. It was ₹1,831 crore in FY24 and ₹1,656 crore in FY23: up 44.7% over three years, 13.1% a year on average.

How were Rossari Biotech's Q2 FY27 results?

Both grew from a year earlier: net profit was up 5.5% at ₹38.9 crore and revenue was up 19.0% at ₹698 crore. The operating margin was 8.2%, down 1.0 percentage points from 9.2% a year earlier. Against Q1 FY27, net profit was up 10.9% and revenue up 0.1%.

What was Rossari Biotech's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹56.9 crore, a margin of 8.2%, against 7.9% in Q1 FY27 and 9.2% in Q2 FY26. EBITDA was ₹87 crore, 12.5% of revenue.

What was Rossari Biotech's net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹74 crore, up 5.0% from ₹70.5 crore in the same months a year earlier. Revenue from operations was ₹1,395 crore, up 23.4%.

How has Rossari Biotech's profit changed over the last four quarters?

Net profit by quarter: ₹32.8 crore in Q3 FY26, ₹46 crore in Q4 FY26, ₹35.1 crore in Q1 FY27 and ₹38.9 crore in Q2 FY27. That is ₹153 crore over the four quarters, up 11.8% from ₹137 crore in the four quarters before. Revenue from operations: ₹582 crore, ₹685 crore, ₹697 crore and ₹698 crore.

When will Rossari Biotech announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Rossari Biotech figures come from?

From Rossari Biotech's own consolidated results filings to NSE, in ₹ crore as filed. Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.